Qiong Xu

Qiong Xu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Infection
Verified
Journal Article
Closed access
HLHui Li
Hui Li
KCKailan Chen
Kailan Chen
MLMaochang Liu
Maochang Liu
HXHua Xu
Hua Xu
QXQiong Xu
Qiong Xu

1 July 2020 in Journal of Clinical Virology
Verified
Journal Article
Closed access
HPHui Peng
Hui Peng
PGPing Gao
Ping Gao
QXQiong Xu
Qiong Xu
MLMaochang Liu
Maochang Liu
JPJing Peng
Jing Peng
HXHua Xu
Hua Xu

3 October 2024 in Food Bioscience
Verified
Journal Article
Closed access
QXQiong Xu
Qiong Xu
MWMiao-Miao Wang
Miao-Miao Wang
XLXinyue Li
Xinyue Li
YDYa-Rui Ding
Ya-Rui Ding
XWXiaoyi Wei
Xiaoyi Wei
TZTao Zhou
Tao Zhou

1 December 2020 in Epilepsy Research
Verified
Journal Article
Open access
MLMaochang Liu
Maochang Liu
JMJunjun Mao
Junjun Mao
HXHua Xu
Hua Xu
JWJing Wang
Jing Wang
PZPeiwei Zhao
Peiwei Zhao
ZDZhaosong Du
Zhaosong Du
This study was conducted to explore the influence of genetic variations on responsiveness to valproic acid (VPA) monotherapy among Chinese children with epilepsy. One hundred and forty epileptic children taking VPA as monotherapy were enrolled, and at least one-year follow-up was obtained to assess the therapeutic outcome. Twenty-seven single nucleotide polymorphisms (SNPs) within twelve candidate genes correlated with the metabolic enzymes, transporters and targets of VPA were genotyped. The effects of selected polymorphisms on VPA efficacy were identified by binary logistic regression analysis adjusting for potential confounders. SCN2A rs2304016 (A > G) AG genotype was more common among the VPA-resistant patients in comparison with the VPA-responsive patients (OR = 3.18, 95 % CI = 1.10-9.14, P = 0.032), and in subgroup of focal seizure, lower frequency of VPA resistance was found in epileptic children with SCN1A rs2298771 AG genotype than those with AA genotype (OR = 0.11, 95 % CI = 0.01-0.91, P = 0.040). Our study indicated that SCN2A rs2304016 and SCN1A rs2298771 polymorphisms might be associated with the response to VPA monotherapy in Chinese epileptic children. Further and larger researches are required to validate these results.

1 November 2019 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
HLHui Li
Hui Li
QXQiong Xu
Qiong Xu
YWYang Wang
Yang Wang
KCKailan Chen
Kailan Chen
JLJianxin Li
Jianxin Li

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
LWLidan Wang
Lidan Wang
KZKai Zheng
Kai Zheng
XLXinlin Li
Xinlin Li
YWYang Wang
Yang Wang
QXQiong Xu
Qiong Xu
Objective. The aim of this study is to evaluate the association of genetic polymorphisms in Cytochrome P450 2D6(CYP2D6) and the change in VEGF levels with the response to propranolol in patients with Infantile hemangiomas (IH). Methods. IH patients who underwent over six months of propranolol therapy and received oral propranolol only were enrolled. The target dose of propranolol was 1 mg kg−1day−1. Deoxyribonucleic acid was obtained from venous blood leukocytes. Genotypes of CYP2D6 (rs1065852 and rs1135840) were tested by polymerase chain reaction (PCR) and by sequencing the products. Baseline serum VEGF and serum VEGF one month after treatment were measured. The clinical responses after six months of treatment were evaluated. Genotypes of CYP2D6 (rs1065852 and rs1135840) and VEGF levels were compared between good responders and poor‐to‐moderate responders. Results. 72 patients were enrolled in the study. Patients with CYP2D6 (rs1135840) G/G homozygote had the highest response rate to propranolol. No significant association was found between the response rates and CYP2D6 (rs1065852) polymorphism. No significant differences were found in baseline serum VEGF, serum VEGF one month after treatment, and VEGF ratio between good responders and poor‐to‐moderate responders. Conclusion. The response to propranolol treatment in IH patients was associated with the gene polymorphism of CYP2D6 (rs1135840). A low‐dose propranolol regimen was effective and safe in young infants with IH. The change of serum VEGF levels after one month’s treatment could not be used to predict the response rate to propranolol.